WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States

Date Published06/08/2020
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name WuXi Biologics
Parent companyWuXi Pharma Tech
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):100
Year reshoring announced:2020
Country(ies) from which reshored:China
City reshored to:Cranbury
State(s) reshored to:NJ
If relevant, work nearshored to:-
Product(s) reshoredbiopharma
What domestic positive factors made reshoring more attractive?Eco-system synergies, Government Incentives, Proximity to customers/market
Find Reshoring Articles